Services

Finding the best model for interaction between the sponsor organization and the vendor can be very challenging.  Implementing that model successfully is absolutely vital to the successful execution of your non-clinical and clinical development plan.  WhiteChurch Consulting has decades of experience of working for both sponsors and CROs.  We will help you to set up the best structure that enables optimal execution with transparency and bilateral accountability.

In today's R&D industry, there is an enormous array of service providers (discovery, toxicology, DMPK, biomarkers, clinical CROs, patient recruitment, SMOs, EDC, PROs, wearables, mobile phlebotomy/nursing, supply chain, IRT, central & esoteric labs, pharmacovigilance, eSource, etc.).  Choosing the best vendors to partner with is a daunting task.  WhiteChurch Consulting can facilitate the evaluation of these service providers, as well as manage them directly.

Protocols have become highly complicated, measuring large numbers of efficacy and safety endpoints.  Although well founded in the desire for scientific rigor, this complexity demands significant operational planning and oversight, as well as very large budgets.  Additionally, investigator sites and patients are detrimentally impacted through wide variances from standard of care.  WhiteChurch Consulting will target the key parameters and thereby facility execution as well as save money.

Our society has become very accustomed to goods and services at our doorstep. This model has now entrenched itself into pharma/biotech R&D, accelerated by the COVID-19 pandemic.  For your investigation to be successful, you must eliminate non-essential points of in-person interaction, and implement a decentralized platform to enable virtual engagement wherever possible.  WhiteChurch Consulting is expert in this area, and will find the right balance of traditional and decentralized models to achieve your goals.

With increasing numbers of expedited approvals for breakthrough and truly novel therapies, regulators are commonly requiring further data compilation and analysis post-launch.  Phase IV trials and observational studies/registries are excellent tools to gather these data in a real world setting.  WhiteChurch Consulting will streamline your post-marketing operational plan, explore pharmaco-economic data for payers and HTAs, and evaluate endpoints to differentiate your product from its competitors.

Defining a compelling value proposition in the pharma/biotech R&D industry is a must-have for both start-ups and established companies alike.  Regardless of whether you need an experienced voice to validate what you have built so far, or if you simply have an idea and don't know how to take the next step, WhiteChurch Consulting can help.  We are the impartial industry veterans who will carefully and thoroughly understand your service, fill gaps, and reinforce differentiators to make you stand out from the crowd!

Selling in the pharma/biotech industry requires a clear articulation of the hurdles your service will surmount, what differentiators are unique to your solution, as well as what your competition is positioning to your client base.  There is also a complex and far-reaching network of established partnerships and preferences already in place.  WhiteChurch Consulting will ensure you address all of these topics, and help you build account plans that focus your team on growth.  We further support data analysis, tool customization, and sales structure optimization as needed.

Are you a growing/young organization with a need for a seasoned leader, but not yet ready to commit to a new executive as a full-time employee? Alternatively, are you an established company with an urgent need for an interim leader while you search for a candidate to fill your unplanned executive gap?  Regardless of where you fall in the continuum of executive need, WhiteChurch Consulting can help fill it.  Our industry veteran team will provide the right skill set over the right timeframe to underpin your success!

  To develop a new therapy, pharma companies can spend hundreds of millions, to billions of dollars (USD), yet only one in 10 product candidates ever makes it to market.  Further, society and payers alike expect truly innovative treatments rather than the 'me too'  compounds of the past.  In this context licensing can offer an opportunity to cut down the development expense and share the burden of risk for all parties.  WhiteChurch will help you identify the ideal target(s) and ensure all pertinent details are clear to enable an informed decision.